Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Single-Arm Study of Maveropepimut-S plus Low-Dose Cyclophosphamide in Platinum-Resistant Epithelial Ovarian Cancer
2022-003666-20Phase 2Completed
- Sponsor
- IMV
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maveropepimut-S in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by IMV. Primary endpoint: Overall Response Rate (ORR) per RECIST. Started Jan 2023; status: completed.
02
Drugs
maveropepimut-S
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-003666-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003666-20.